Galmed Pharmaceuticals (GLMD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GLMD · Stock Price

USD 0.63-0.61 (-49.52%)

Market Cap: $4.2M

Historical price data

Market Cap: $4.2MPipeline: 13 drugs (1 Phase 3)Founded: 2000HQ: Tel Aviv, Israel

Sector Ranking#367 in Small Molecule Drugs

Overview

Galmed Pharmaceuticals' mission is to develop 'lifetime medicine' for metabolic and inflammatory diseases, leveraging its proprietary Fatty Acid Bile Acid Conjugate (FABAC) platform. Its primary achievement is advancing Aramchol, a liver-targeted SCD1 modulator, into a global Phase 3 registrational trial (ARMOR) for NASH with fibrosis, following promising Phase 2b data. The company's strategy involves executing the ARMOR trial while exploring strategic options to unlock value from its clinical asset and preclinical pipeline. However, its path is marked by significant financial constraints and intense competition in the NASH landscape.

Liver Diseases (NASH/Fibrosis)Inflammatory Diseases

Technology Platform

Proprietary Fatty Acid Bile Acid Conjugate (FABAC) platform, creating synthetic hybrid molecules designed for liver-targeted modulation of metabolic and inflammatory pathways.

Pipeline

13

13 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Aramchol free acid + Placebo	Nonalcoholic Steatohepatitis (NASH)	Phase 3
Aramchol meglumine	Primary Sclerosing Cholangitis	Phase 2
Aramchol + Placebo	Gallstones	Phase 2
Aramchol	Fatty Liver	Phase 2
Aramchol + Placebo	Healthy Volunteers	Phase 1

Funding History

3

Total raised:$55M

PIPE$18MUndisclosedNov 15, 2019

IPO$25MUndisclosedFeb 15, 2014

Series A$12MUndisclosedSep 15, 2010

Opportunities

Success in the Phase 3 ARMOR trial could unlock the massive, untapped NASH market, with Aramchol's favorable safety profile positioning it as a chronic therapy.

The FABAC platform also offers potential for expansion into other metabolic and inflammatory indications.

Risk Factors

Extreme financial constraints and Nasdaq delisting risk threaten the company's ability to complete its Phase 3 trial.

The clinical path for Aramchol remains high-risk in a competitive NASH landscape, and the company lacks commercialization capabilities.

Competitive Landscape

Galmed faces intense competition from well-funded players like Madrigal (approved therapy), Novo Nordisk (GLP-1 agonists), and others. Aramchol's differentiation hinges on its SCD1 mechanism and safety, but it must demonstrate competitive efficacy in fibrosis improvement to secure a market position.